The sixth edition of the FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration has been published and will become effective on June 1, 2015. All FACT-accredited cellular therapy organizations must comply with these Standards at this time. These Hematopoietic Cell Therapy Standards apply to hematopoietic progenitor cells, defined as self-renewing and/or multi-potent stem cells capable of maturation into any of the hematopoietic lineages, lineage-restricted pluri-potent progenitor cells, and committed progenitor cells from hematopoietic sources (bone marrow, umbilical cord blood, peripheral blood, or other tissue source). These Standards also include mononuclear cells, defined as nucleated cells from any hematopoietic tissue source (marrow, peripheral blood, umbilical cord, and placental blood) collected for therapeutic use other than as hematopoietic progenitor cells. The Standards and accompanying Accreditation Manual, crosswalks, and summary of changes are all available on the FACT website for reference. Printed copies of the Standards and Accreditation Manual may be purchased from the FACT store.

Ask FACT

FAQ

Ask a Peer
FACT Consulting

Accreditation Success Story

The Héma-Québec Public Cord Blood Bank (CBB) was created in 2004 to meet the needs of Quebecers and to contribute to the international effort towards a high-quality global inventory of cord blood units. Read more